News and Trends 20 May 2020 Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II MGB Biopharma has reported positive results from a phase II trial showing that its antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after. The bacterium Clostridium difficile causes life-threatening infections in the intestine and is the most common cause of diarrhea. Current treatments against it […] May 20, 2020 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2020 Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […] May 19, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 18 May 2020 Will Covid-19 Change the Face of Vaccine Development? The unprecedented scale of the current Covid-19 pandemic has led to a vaccine ‘race’ the like of which has never been seen before. This may change the face of vaccine development forever. Since the English physician Edward Jenner invented the first smallpox vaccine in 1796, vaccines have resulted in dramatic reductions in deaths from previously […] May 18, 2020 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2020 Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats Update (18/05/2020): Cubiq Foods has received a €5M investment from food technology investor Blue Horizon Ventures. With the funds, the startup aims to accelerate the production of its omega 3 fat additives based on cell culture, expecting to launch two products by the end of the year. 31/01/2019 Based in Barcelona, Cubiq Foods is developing […] May 18, 2020 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Affibody Signs €208M Deal To Market Autoimmune Drug in China Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […] May 15, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic droplets, which could lead to the production of organic chemicals and clean fuels that is more efficient than nature can achieve alone. In a study recently published in Science, the research team developed an automated way to produce artificial versions […] May 15, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Update: ADC Therapeutics’ IPO Hits Above Target with €215M Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […] May 15, 2020 - 4 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2020 Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations and driving the launch of its targeted chemotherapy drug in the US. In what could be one of European biotech’s largest equity boosts this year, the company exceeded initial plans to raise €111M (SEK 1.2M) through Nasdaq Stockholm following a […] May 14, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2020 EU Initiative Pumps up Funding for Covid-19 Research to €117M The funding will go towards eight research projects that have been selected out of 144 proposals received by the EU’s Innovative Medicines Initiative. In March, the Innovative Medicines Initiative (IMI) opened a fast-track call for proposals on diagnostics and treatments for the coronavirus outbreak. Due to the large number of high-quality proposals received, the IMI […] May 14, 2020 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2020 Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […] May 13, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2020 Gamida Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase III A rapid-acting bone marrow transplant developed by the Israeli biotech Gamida Cell was engrafted in blood cancer patients 10 days faster than standard umbilical cord blood transplants in a phase III trial. The trial recruited 125 blood cancer patients in more than 50 clinical centers globally. One group received a standard transplant of donor umbilical […] May 12, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2020 Italian Pharma Getting Back to Normal With Two Biotech Acquisitions Despite the country being hard hit with Covid-19, Italian pharma seems to be getting back to business as usual with two oncology-related biotech acquisitions in the last week. The most recent acquisition was of French immuno-oncology company ElsaLys Biotech by Mediolanum Farmaceutici, a pharmaceutical group based in Milan. The French biotech has several candidate drugs […] May 11, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email